Late-stage trial shows MS drug effectiveness, Novartis says

12/14/2008 | Wall Street Journal, The

Novartis AG reported preliminary data from a late-stage trial showing that 0.5 mg and 1.25 mg doses of FTY720, a drug candidate for multiple sclerosis, were more effective in reducing relapse than Avonex, an injectable drug from Biogen Idec. Novartis said it may seek FDA approval for FTY720 at the end of next year.

View Full Article in:

Wall Street Journal, The

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Senior Director, Research
America's Health Insurance Plans (AHIP)
Washington, DC
Stop Loss Sales Executive
Blue Cross Blue Shield of MA
Boston, MA
Regional Director, Southeastern Region - State Affairs
America's Health Insurance Plans (AHIP)
Washington, DC
Field Representative-Oklahoma and Kansas
National Rural Electric Cooperative Association (NRECA)
Multiple Locations, SL_Multiple Locations
Market Intelligence Manager
Olympus Corporation of the Americas
Southborough, MA